Gut Microbiome Study Yields Clues to Melanoma Development, Progression
(MedPage Today) -- A comparative analysis of fecal bacteria revealed distinct differences between patients with melanoma and healthy volunteers and between patients with early- versus late-stage melanoma.
Patients with melanoma had a higher abundance... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 1, 2023 Category: Dermatology Source Type: news
Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma
(MedPage Today) -- Combined BRAF-MEK inhibition for advanced BRAF-mutant melanoma led to significantly better progression-free survival (PFS) as compared with single-agent BRAF inhibition, according to a randomized trial.
Patients who received... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 29, 2023 Category: Hematology Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
Skin cancer warning ahead of bank holiday weekend - even though temperatures only set to peak at 21C
Brits have been urged to use sunscreen, wear a hat and spend time in the shade by Melanoma Focus to protect themselves against the most serious type of skin cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - August 25, 2023 Category: Consumer Health News Source Type: news
Advances in surgery are improving survival for people with melanoma
The National Cancer Institute estimates that 97,610 people will be diagnosed with melanoma in 2023, making up 5% of all new cancer diagnoses. Fortunately, screening and treatment have improved, allowing care teams to catch melanoma earlier when it's easier to treat. As a result, the number of people who survive the disease has steadily increased. Tina Hieken, M.D., a Mayo Clinic surgical oncologist with a particular interest in melanoma, answers questions about treatment and advances in surgery that… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 24, 2023 Category: Databases & Libraries Source Type: news
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
WEDNESDAY, Aug. 23, 2023 -- For patients with metastatic melanoma who receive frontline anti-programmed death protein 1 (PD-1) or therapy against programmed cell death 1 ligand 1 and whose tumors progressed with cytotoxic T-lymphocyte protein 4... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 23, 2023 Category: Pharmaceuticals Source Type: news
Neoadj T-VEC May Improve Survival in Resectable Melanoma Neoadj T-VEC May Improve Survival in Resectable Melanoma
Offering talimogene laherparepvec before surgery compared with surgery alone could improve event-free as well as overall survival in patients with advanced resectable melanoma, a new analysis suggests.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 22, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Five skin cancer red flags to look out for as Chris Evans reveals melanoma diagnosis
If you spot any of these worrying signs you should seek medical advice as soon as possible. (Source: Daily Express - Health)
Source: Daily Express - Health - August 21, 2023 Category: Consumer Health News Source Type: news
Six bizarre signs of skin cancer revealed after radio legend Chris Evans' diagnosis
The 57-year-old today told listeners of his Virgin Radio show that his melanoma was found in the extremely early stages and he is hoping to make a full recovery. (Source: the Mail online | Health)
Source: the Mail online | Health - August 21, 2023 Category: Consumer Health News Source Type: news
Immunotherapy drug combo helps extend lives of people with metastatic melanoma
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to widely used immunotherapy drugs called PD-1 inhibitors.In clinical trials, the investigators found that the combination therapy could extend the amount of time patients live without their cancer worsening, known as progression-free survival, and that it helps overcome their resistance to prior immunotherapies — which would allow more people to benefit from the treatment.The study evaluated the use of the imm...
Source: UCLA Newsroom: Health Sciences - August 18, 2023 Category: Universities & Medical Training Source Type: news
Episode 4: Liquid Biopsy in Melanoma Episode 4: Liquid Biopsy in Melanoma
Drs Sapna Patel and David Polsky explore biomarker development and the clinical utilization of liquid biopsy in melanoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT ™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time NEW YORK, Aug. 14,…#hepzatokit #fda #businessupdatecall #easterntime #delcathsystems #nccn #php #hepzatokitmarks #gerardmichel #nct02678572 (Source: Reuters: Health)
Source: Reuters: Health - August 16, 2023 Category: Consumer Health News Source Type: news
FDA OKs First Liver-Directed Treatment for Metastatic Uveal Melanoma
(MedPage Today) -- The FDA announced approval of the Hepzato Kit melphalan injection system as liver-directed therapy for uveal melanoma metastases.
The approval stipulates use in adults with unresectable liver metastases that affects less than... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 15, 2023 Category: American Health Source Type: news
FDA approves melphalan as a liver-directed treatment for uveal melanoma
On August 14, 2023, the Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery System) containing melphalan (HEPZATO, Delcath Systems, Inc.) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 15, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
